Caris signs Genentech deal worth up to $1.1 billion for rare cancer targets
I'm PortAI, I can summarize articles.
Caris Life Sciences has entered a multi-year collaboration with Genentech, a part of Roche, to discover new drug targets for hard-to-treat cancers. The deal includes $25 million in upfront payments and could total up to $1.1 billion in milestone payments. Caris will also receive royalties on therapies developed. The partnership combines Caris' precision medicine platform with Genentech's drug development capabilities to tackle solid tumors.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments